{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:24:54Z","timestamp":1780982694981,"version":"3.54.1"},"reference-count":15,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences","award":["# CO-US-380-5423"],"award-info":[{"award-number":["# CO-US-380-5423"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: HIV and hepatitis B virus (HBV) coinfection has been associated with a higher risk of morbidity and mortality. HBV-active antiretroviral regimens have significantly improved the outcomes for coinfected people. Although bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) is safe and efficacious for the treatment of HIV, there are few randomized studies on the treatment of HIV\/HBV coinfection. Methods: This open-label switch study enrolled adults with HIV\/HBV coinfection from two clinical centers. The participants were switched from their current antiretroviral regimen (regardless of viral suppression) to BIC\/FTC\/TAF, taken once daily for 48 weeks. The primary endpoints were the proportion of participants with HIV RNA &lt; 50 copies\/mL and HBV DNA &lt; 29 IU\/mL at Week 24. Results: Twenty-eight participants were enrolled, with a median age of 51 years; the majority were Black (89%) and male (86%). At baseline, 71% (20\/28) and 79% (22\/28) were HIV- and HBV-suppressed, respectively, and 64% (18\/28) exhibited suppression for both. At week 24, 89% (25\/28) and 86% (24\/28) were HIV- and HBV-suppressed, respectively, and 82% (23\/28) exhibited suppression for both. The most common treatment-related adverse event was nausea (2\/28). None of the participants discontinued the treatment due to an adverse event. No serious adverse events or hepatitis flares were observed. Conclusion: BIC\/FTC\/TAF is a safe and suitable option for the treatment of HIV\/HBV-coinfected patients.<\/jats:p>","DOI":"10.3390\/v17040510","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:21:41Z","timestamp":1743495701000},"page":"510","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Adults with HIV\/HBV Coinfection: An Open-Label, Single-Arm, Safety and Efficacy Switch Study"],"prefix":"10.3390","volume":"17","author":[{"given":"Helena","family":"Kwakwa","sequence":"first","affiliation":[{"name":"Newlands Health, Philadelphia, PA 19114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Bran","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ruff","sequence":"additional","affiliation":[{"name":"Newlands Health, Philadelphia, PA 19114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Sharaf","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunuk","family":"Seung","sequence":"additional","affiliation":[{"name":"Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Choe","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-4672","authenticated-orcid":false,"given":"Joel V.","family":"Chua","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2023). Epidemiological Fact Sheet: HIV Statistics, Globally and by WHO Region, 2023, WHO. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/j0294-who-hiv-epi-factsheet-v7.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","article-title":"HIV-hepatitis B virus coinfection: Epidemiology, pathogenesis, and treatment","volume":"31","author":"Singh","year":"2017","journal-title":"Aids"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jvh.13217","article-title":"Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis","volume":"27","author":"Platt","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/hep.510290447","article-title":"Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men","volume":"29","author":"Colin","year":"1999","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14598","DOI":"10.3748\/wjg.v20.i40.14598","article-title":"Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review","volume":"20","author":"Sun","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): A randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): A double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"E640","DOI":"10.1016\/S2352-3018(23)00151-0","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): A double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV [Internet]"},{"key":"ref_11","unstructured":"Rockstroh, J.K., Sax, P.E., Daar, E.S., Walmsley, S., Workowski, K., Orkin, C., Arribas, J.R., DeJesus, E., Wohl, D., and Molina, J.-M. (2025, March 24). High HBV and HIV Suppression with Treatment of HIV\/HBV Coinfection in B\/F\/TAF Studies. Presented at Conference on Retroviruses and Opportunistic Infections (Boston, MA) Abstract 618, 4\u20137 March 2018. Available online: https:\/\/www.natap.org\/2018\/CROI\/croi_73.htm."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bello, K.J., Mesner, O., O\u2019Bryan, T.A., Won, S.H., Lalani, T., Ganesan, A., Agan, B.K., and Okulicz, J.F. (2016). Factors associated with 10 years of continuous viral load suppression on HAART. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1677-x"},{"key":"ref_13","unstructured":"CDC (2020). HIV Surveillance Special Report, Center for Disease Control and Prevention."},{"key":"ref_14","first-page":"203","article-title":"Hepatitis delta virus epidemiology in the industrialized world","volume":"22","author":"Toy","year":"2020","journal-title":"AIDS Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.15921","article-title":"Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta-analysis","volume":"44","author":"Wong","year":"2024","journal-title":"Liver Int."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/4\/510\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:07:15Z","timestamp":1760029635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/4\/510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["v17040510"],"URL":"https:\/\/doi.org\/10.3390\/v17040510","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}